欧普康视1月6日获融资买入5127.12万元，融资余额6.09亿元

Core Viewpoint - The company Ophthalmic Vision Technology Co., Ltd. (欧普康视) has shown a mixed financial performance with slight revenue growth but a significant decline in net profit, indicating potential challenges ahead in maintaining profitability while managing investor sentiment and market position [2][3]. Financing and Trading Activity - On January 6, the stock price of Ophthalmic Vision increased by 1.69%, with a trading volume of 463 million yuan. The financing buy-in amount for the day was 51.27 million yuan, while the financing repayment was 46.70 million yuan, resulting in a net financing buy of 457.09 thousand yuan. The total financing and securities balance reached 613 million yuan [1]. - The current financing balance of 609 million yuan accounts for 4.20% of the circulating market value, which is above the 60th percentile level over the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 900 shares were repaid, and 195,900 shares were sold short, amounting to 3.18 million yuan at the closing price. The remaining short selling volume was 269,000 shares, with a balance of 4.36 million yuan, also above the 50th percentile level over the past year [1]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 1.433 billion yuan, reflecting a year-on-year growth of 0.13%. However, the net profit attributable to shareholders decreased by 15.41% to 442 million yuan [2]. - Since its A-share listing, the company has distributed a total of 949 million yuan in dividends, with 576 million yuan distributed over the past three years [3]. Shareholder Structure - As of December 19, the number of shareholders for Ophthalmic Vision was 61,900, a slight decrease of 0.02% from the previous period. The average circulating shares per person increased by 0.02% to 10,797 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by major ETFs, such as Huabao Zhongzheng Medical ETF and E Fund Growth ETF, while a new shareholder, Penghua Medical Technology Stock A, entered the top ten with 3.90 million shares [3].